Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Decoding the impact of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer through tumor evolution analysis

Tingjie Wang, Lingxi Tian, Bing Wei, Jun Li, Cuiyun Zhang, Ruitao Long, Xiaofei Zhu, Yougai Zhang, Bo Wang, Jun Yang, Yongjun Guo
doi: https://doi.org/10.1101/2024.06.11.24308797
Tingjie Wang
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingxi Tian
3MOE Key Laboratory of Intelligent Biomanufacturing, School of Bioengineering, Dalian University of Technology, Dalian 116024, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bing Wei
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Li
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cuiyun Zhang
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruitao Long
5School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofei Zhu
4Department of clinical laboratory, the third affiliated hospital of Xinxiang Medical University,
6Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Key Laboratory of Tumor Microenvironment and Immunotherapy, School of Medical Technology, Xinxiang Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yougai Zhang
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Wang
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Yang
3MOE Key Laboratory of Intelligent Biomanufacturing, School of Bioengineering, Dalian University of Technology, Dalian 116024, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yongjunguo{at}hotmail.com junyang{at}dlut.edu.cn
Yongjun Guo
1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yongjunguo{at}hotmail.com junyang{at}dlut.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tumor heterogeneity is associated with poor prognosis and drug resistance, leading to therapeutic failure. Here, we aim to utilize tumor evolution analysis to decode the intra- and inter-tumoral heterogeneity of high-grade serous ovarian cancer (HGSOC), unraveling the correlation between tumor heterogeneity and prognosis as well as chemotherapy response through single-cell and spatial transcriptomic analysis.

Methods We collected and curated 28 HGSOC patients single-cell transcriptomic data from five datasets. Then, we developed a novel text mining-based machine learning approach to deconstruct the evolutionary patterns of tumor cell functions. This allowed us to identify key tumor-related genes within different evolutionary branches, elucidate the microenvironmental cell compositions that various functional tumor cells depend on, and analyze the intra- and inter-heterogeneity of tumors and their microenvironments in relation to prognosis and chemotherapy response in HGSOC patients. We further validated our findings in two spatial and seven bulk transcriptomic datasets, totally 1,030 patients.

Results By employing transcriptomic clusters as proxies for functional clonality, we identified a significant increase in tumor cell state heterogeneity, which was strongly correlated with patient prognosis and treatment response. Furthermore, increased intra- and inter-tumoral functional clonality was associated with the characteristics of cancer-associated fibroblast (CAF). We also found that the spatial proximity between CXCL12-positive CAF and tumor cells, mediated through the CXCL12/CXCR4 interaction, is highly positively correlated with poor prognosis and chemotherapy resistance in HGSOC. Finally, we constructed a panel of 24 genes through statistical modeling, that are highly correlated with CXCL12-positive fibroblasts and can predict both prognosis and chemotherapy response in HGSOC.

Conclusions Our study offers insights into the collective behavior of tumor cell communities in HGSOC, as well as potential drivers of tumor evolution in response to therapy. Functional analyses and experiments revealed a strong association between CXCL12-positive fibroblasts and tumor progression as well as treatment outcomes. Our findings provide an important theoretical basis for clinical HGSOC treatment.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the co-sponsored by the Henan Province and Ministry of Health of Medical Science and Technology Program (SBGJ202302028 for Tingjie Wang), This research was supported by the Dalian Science and Technology Innovation Fund (2022JJ12SN049 for Jun Yang), the Fundamental Research Funds for the Central Universities.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Availability of data

The datasets analyzed in this study are available from the gene expression omnibus (GEO) repository under the accession numbers in supplementary tables.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 12, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Decoding the impact of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer through tumor evolution analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Decoding the impact of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer through tumor evolution analysis
Tingjie Wang, Lingxi Tian, Bing Wei, Jun Li, Cuiyun Zhang, Ruitao Long, Xiaofei Zhu, Yougai Zhang, Bo Wang, Jun Yang, Yongjun Guo
medRxiv 2024.06.11.24308797; doi: https://doi.org/10.1101/2024.06.11.24308797
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Decoding the impact of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer through tumor evolution analysis
Tingjie Wang, Lingxi Tian, Bing Wei, Jun Li, Cuiyun Zhang, Ruitao Long, Xiaofei Zhu, Yougai Zhang, Bo Wang, Jun Yang, Yongjun Guo
medRxiv 2024.06.11.24308797; doi: https://doi.org/10.1101/2024.06.11.24308797

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)